The Center for Biosimilars® recaps the top news for the week of November 5, 2018.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 5.
Number 5: Oncobiologics has announced that it has dosed the first patients with wet age-related macular degeneration in a clinical trial of ONS-5010, an ophthalmic bevacizumab candidate.
Number 4: Three attorneys from Goodwin hosted a webinar this week to provide updates on topics ranging from the Biologics Price Competition and Innovation Act Litigation, the Patent Trial and Appeal Board, and recent regulatory and FDA issues related to biosimilars.
Number 3: Regeneron posted positive third quarter earnings results for 2018 that show aflibercept sales in the United States increased 7 percent to 1.02 billion dollars versus third quarter 2017 results.
Number 2: Momenta Pharmaceuticals recently announced that it has reached a settlement with Humira-maker AbbVie over a proposed biosimilar adalimumab, M923.
Number 1: Sandoz announced this week that it will no longer pursue FDA approval for its biosimilar rituximab, GP2013.
Finally, last week, our e-newsletter asked if the eventual approval of upadacitinib could curb the uptake of biosimilar infliximab.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.